HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Head and neck squamous cell carcinoma (HNSCC) is a significant health concern.
• HRAS mutations are emerging as actionable oncogene drivers in HNSCC.
• Understanding the clinical implications of HRAS mutations is crucial for targeted therapy development.

Purpose of the Study:

• To evaluate HRAS mutational variants in HNSCC.
• To analyze the comutation profile of HRAS-mutant HNSCC.
• To determine the survival outcomes for this molecularly defined patient population.

Main Methods:

• Leveraged four deidentified patient datasets including HNSCC with HRAS mutations.
• Extracted demographic, clinical, and mutational data (HRAS type, co-occurring mutations).
• Analyzed survival outcomes using the Kaplan-Meier method.

Main Results:

• Identified 249 patients with HRAS-mutant HNSCC; G12S was the most common mutation (29%).
• HRAS-mutant HNSCC predominantly occurred in HPV-negative patients and showed distinct co-occurring mutations (e.g., CASP8, TERT, NOTCH1).
• Patients experienced poor outcomes (high recurrence, short DFS and OS), but tipifarnib treatment showed improved OS.

Conclusions:

• HRAS mutations, particularly G12S, are found in 3-4% of HNSCC and are associated with poor outcomes without targeted therapy.
• The distinct comutation pattern of HRAS-mutant HNSCC offers insights for future combination therapy strategies.
• Tipifarnib demonstrates a potential to improve overall survival in this patient group.